Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 372

1.

Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.

Tarver TC, Hill JE, Rahmat L, Perl AE, Bahceci E, Mori K, Smith CC.

Blood Adv. 2020 Feb 11;4(3):514-524. doi: 10.1182/bloodadvances.2019000919.

PMID:
32040554
2.

Metabolic pathways mediate pathogenesis and offer targets for treatment in rheumatic diseases.

Wyman B, Perl A.

Curr Opin Rheumatol. 2020 Mar;32(2):184-191. doi: 10.1097/BOR.0000000000000687.

PMID:
31895126
3.

Post-sepsis syndrome - an evolving entity that afflicts survivors of sepsis.

Mostel Z, Perl A, Marck M, Mehdi SF, Lowell B, Bathija S, Santosh R, Pavlov VA, Chavan SS, Roth J.

Mol Med. 2019 Dec 31;26(1):6. doi: 10.1186/s10020-019-0132-z. Review.

4.

Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia.

Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, Mangan JK, Loren AW, Perl AE, Maude SL, Grupp SA, Shah NN, Gilmore J, Lacey SF, Melenhorst JJ, Levine BL, June CH, Porter DL.

J Clin Oncol. 2020 Feb 10;38(5):415-422. doi: 10.1200/JCO.19.01892. Epub 2019 Dec 9.

PMID:
31815579
5.

Lupus-associated endogenous retroviral LTR polymorphism and epigenetic imprinting promote HRES-1/RAB4 expression and mTOR activation.

Godavarthy A, Kelly R, Jimah J, Beckford M, Caza T, Fernandez D, Huang N, Duarte M, Lewis J, Fadel HJ, Poeschla EM, Banki K, Perl A.

JCI Insight. 2020 Jan 16;5(1). pii: 134010. doi: 10.1172/jci.insight.134010.

6.

Transaldolase haploinsufficiency in subjects with acetaminophen-induced liver failure.

Oaks Z, Jimah J, Grossman CC, Beckford M, Kelly R, Banerjee S, Niland B, Miklossy G, Kuloglu Z, Kansu A, Lee W, Szonyi L, Banki K, Perl A.

J Inherit Metab Dis. 2019 Nov 26. doi: 10.1002/jimd.12197. [Epub ahead of print]

PMID:
31769880
7.

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.

Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ.

N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688.

PMID:
31665578
8.

Protein phosphatase 2A controls ongoing DNA replication by binding to and regulating cell division cycle 45 (CDC45).

Perl AL, O'Connor CM, Fa P, Mayca Pozo F, Zhang J, Zhang Y, Narla G.

J Biol Chem. 2019 Nov 8;294(45):17043-17059. doi: 10.1074/jbc.RA119.010432. Epub 2019 Sep 27.

PMID:
31562245
9.

Improving Response to FLT3 Inhibitors-BCL2 the Rescue?

Perl AE.

Clin Cancer Res. 2019 Nov 15;25(22):6567-6569. doi: 10.1158/1078-0432.CCR-19-2339. Epub 2019 Sep 12.

PMID:
31515455
10.

Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia.

McMahon CM, Perl AE.

Expert Rev Clin Pharmacol. 2019 Sep;12(9):841-849. doi: 10.1080/17512433.2019.1657009. Epub 2019 Aug 27. Review.

PMID:
31454267
11.

Availability of FLT3 inhibitors: how do we use them?

Perl AE.

Blood. 2019 Aug 29;134(9):741-745. doi: 10.1182/blood.2019876821. Epub 2019 Jun 26. Review.

PMID:
31243041
12.

Longitudinal targeted next-generation sequencing in a patient with acute myeloid leukaemia.

Velu PD, Perl AE, Luger SM, Bagg A, Morrissette JJD.

Br J Haematol. 2019 Sep;186(6):801. doi: 10.1111/bjh.16048. Epub 2019 Jun 17. No abstract available.

PMID:
31206598
13.

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.

Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Hall AC, Jacoby M, Lancet J, LeBlanc TW, Mannis G, Marcucci G, Martin MG, Mims A, O'Donnell MR, Olin R, Peker D, Perl A, Pollyea DA, Pratz K, Prebet T, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wieduwilt M, Gregory KM; OCN, Hammond L, Ogba N.

J Natl Compr Canc Netw. 2019 Jun 1;17(6):721-749. doi: 10.6004/jnccn.2019.0028.

PMID:
31200351
14.

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.

Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, Krämer A, Dombret H, Hogge D, Jonas BA, Leung AY, Mehta P, Montesinos P, Radsak M, Sica S, Arunachalam M, Holmes M, Kobayashi K, Namuyinga R, Ge N, Yver A, Zhang Y, Levis MJ.

Lancet Oncol. 2019 Jul;20(7):984-997. doi: 10.1016/S1470-2045(19)30150-0. Epub 2019 Jun 4. Erratum in: Lancet Oncol. 2019 Jul;20(7):e346.

PMID:
31175001
15.

Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia.

McMahon CM, Canaani J, Rea B, Sargent RL, Qualtieri JN, Watt CD, Morrissette JJD, Carroll M, Perl AE.

Blood Adv. 2019 May 28;3(10):1581-1585. doi: 10.1182/bloodadvances.2018029496. No abstract available.

16.

Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.

McMahon CM, Ferng T, Canaani J, Wang ES, Morrissette JJD, Eastburn DJ, Pellegrino M, Durruthy-Durruthy R, Watt CD, Asthana S, Lasater EA, DeFilippis R, Peretz CAC, McGary LHF, Deihimi S, Logan AC, Luger SM, Shah NP, Carroll M, Smith CC, Perl AE.

Cancer Discov. 2019 Aug;9(8):1050-1063. doi: 10.1158/2159-8290.CD-18-1453. Epub 2019 May 14.

PMID:
31088841
17.

Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study.

Kayser S, Hills RK, Luskin MR, Brunner AM, Terré C, Westermann J, Menghrajani K, Shaw C, Baer MR, Elliott MA, Perl AE, Ráčil Z, Mayer J, Zak P, Szotkowski T, de Botton S, Grimwade D, Mayer K, Walter RB, Krämer A, Burnett AK, Ho AD, Platzbecker U, Thiede C, Ehninger G, Stone RM, Röllig C, Tallman MS, Estey EH, Müller-Tidow C, Russell NH, Schlenk RF, Levis MJ.

Haematologica. 2020 Jan;105(1):161-169. doi: 10.3324/haematol.2018.208678. Epub 2019 Apr 19.

18.

An obligatory role for club cells in preventing obliterative bronchiolitis in lung transplants.

Liu Z, Liao F, Scozzi D, Furuya Y, Pugh KN, Hachem R, Chen DL, Cano M, Green JM, Krupnick AS, Kreisel D, Perl AKT, Huang HJ, Brody SL, Gelman AE.

JCI Insight. 2019 Apr 16;5. pii: 124732. doi: 10.1172/jci.insight.124732.

19.

Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia.

Sung PJ, Sugita M, Koblish H, Perl AE, Carroll M.

Blood Adv. 2019 Apr 9;3(7):1061-1072. doi: 10.1182/bloodadvances.2018029850.

20.

Pathogenesis and treatment of autoimmune rheumatic diseases.

Liu E, Perl A.

Curr Opin Rheumatol. 2019 May;31(3):307-315. doi: 10.1097/BOR.0000000000000594.

PMID:
30920455
21.

RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth.

Umesalma S, Kaemmer CA, Kohlmeyer JL, Letney B, Schab AM, Reilly JA, Sheehy RM, Hagen J, Tiwari N, Zhan F, Leidinger MR, O'Dorisio TM, Dillon J, Merrill RA, Meyerholz DK, Perl AL, Brown BJ, Braun TA, Scott AT, Ginader T, Taghiyev AF, Zamba GK, Howe JR, Strack S, Bellizzi AM, Narla G, Darbro BW, Quelle FW, Quelle DE.

J Clin Invest. 2019 Mar 4;130:1641-1653. doi: 10.1172/JCI123049. eCollection 2019 Mar 4.

22.

Single cell RNA analysis identifies cellular heterogeneity and adaptive responses of the lung at birth.

Guo M, Du Y, Gokey JJ, Ray S, Bell SM, Adam M, Sudha P, Perl AK, Deshmukh H, Potter SS, Whitsett JA, Xu Y.

Nat Commun. 2019 Jan 3;10(1):37. doi: 10.1038/s41467-018-07770-1.

23.

Advances in patient care through increasingly individualized therapy.

DiNardo CD, Perl AE.

Nat Rev Clin Oncol. 2019 Feb;16(2):73-74. doi: 10.1038/s41571-018-0156-2. No abstract available.

PMID:
30602758
24.

mTOR-dependent autophagy contributes to end-organ resistance and serves as target for treatment in autoimmune disease.

Perl A.

EBioMedicine. 2018 Oct;36:12-13. doi: 10.1016/j.ebiom.2018.09.033. Epub 2018 Sep 24. No abstract available.

25.

Management of primary refractory acute myeloid leukemia in the era of targeted therapies.

McMahon CM, Perl AE.

Leuk Lymphoma. 2019 Mar;60(3):583-597. doi: 10.1080/10428194.2018.1504937. Epub 2018 Sep 20.

PMID:
30234399
26.

Sirolimus for systemic lupus erythematosus - Authors' reply.

Perl A, Lai ZW, Kelly R, Faraone SV, Phillips PE.

Lancet. 2018 Sep 1;392(10149):734. doi: 10.1016/S0140-6736(18)31794-X. No abstract available.

PMID:
30191826
27.

MEG3 is increased in idiopathic pulmonary fibrosis and regulates epithelial cell differentiation.

Gokey JJ, Snowball J, Sridharan A, Speth JP, Black KE, Hariri LP, Perl AT, Xu Y, Whitsett JA.

JCI Insight. 2018 Sep 6;3(17). pii: 122490. doi: 10.1172/jci.insight.122490. eCollection 2018 Sep 6.

28.

Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors.

Schwartz GW, Manning B, Zhou Y, Velu P, Bigdeli A, Astles R, Lehman AW, Morrissette JJD, Perl AE, Li M, Carroll M, Faryabi RB.

Clin Cancer Res. 2019 Jan 15;25(2):573-583. doi: 10.1158/1078-0432.CCR-18-0655. Epub 2018 Sep 4.

29.

Systemic lupus erythematosus-myasthenia gravis overlap syndrome: Presentation and treatment depend on prior thymectomy.

Minchenberg SB, Chaparala G, Oaks Z, Banki K, Perl A.

Clin Immunol. 2018 Sep;194:100-104. doi: 10.1016/j.clim.2018.07.007. Epub 2018 Jul 17.

30.

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML.

Cortes JE, Tallman MS, Schiller GJ, Trone D, Gammon G, Goldberg SL, Perl AE, Marie JP, Martinelli G, Kantarjian HM, Levis MJ.

Blood. 2018 Aug 9;132(6):598-607. doi: 10.1182/blood-2018-01-821629. Epub 2018 Jun 6.

31.

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

Cortes J, Perl AE, Döhner H, Kantarjian H, Martinelli G, Kovacsovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman JK, Baldus CD, Burnett A, Krämer A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M.

Lancet Oncol. 2018 Jul;19(7):889-903. doi: 10.1016/S1470-2045(18)30240-7. Epub 2018 May 31.

PMID:
29859851
32.

Measurement of Mitochondrial Mass by Flow Cytometry during Oxidative Stress.

Doherty E, Perl A.

React Oxyg Species (Apex). 2017 Jul;4(10):275-283. doi: 10.20455/ros.2017.839. Epub 2017 Jul 1.

33.

Metabolism as a Target for Modulation in Autoimmune Diseases.

Huang N, Perl A.

Trends Immunol. 2018 Jul;39(7):562-576. doi: 10.1016/j.it.2018.04.006. Epub 2018 May 5. Review.

PMID:
29739666
34.

A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations.

Levis MJ, Perl AE, Altman JK, Gocke CD, Bahceci E, Hill J, Liu C, Xie Z, Carson AR, McClain V, Stenzel TT, Miller JE.

Blood Adv. 2018 Apr 24;2(8):825-831. doi: 10.1182/bloodadvances.2018015925.

35.

Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition.

Kasner MT, Mick R, Jeschke GR, Carabasi M, Filicko-O'Hara J, Flomenberg N, Frey NV, Hexner EO, Luger SM, Loren AW, Mangan JK, Wagner JL, Weiss M, Carroll M, Perl AE.

Invest New Drugs. 2018 Aug;36(4):657-666. doi: 10.1007/s10637-018-0585-x. Epub 2018 Apr 2.

36.

Active epithelial Hippo signaling in idiopathic pulmonary fibrosis.

Gokey JJ, Sridharan A, Xu Y, Green J, Carraro G, Stripp BR, Perl AT, Whitsett JA.

JCI Insight. 2018 Mar 22;3(6). pii: 98738. doi: 10.1172/jci.insight.98738.

37.

Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial.

Lai ZW, Kelly R, Winans T, Marchena I, Shadakshari A, Yu J, Dawood M, Garcia R, Tily H, Francis L, Faraone SV, Phillips PE, Perl A.

Lancet. 2018 Mar 24;391(10126):1186-1196. doi: 10.1016/S0140-6736(18)30485-9. Epub 2018 Mar 15.

38.

Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer.

McClinch K, Avelar RA, Callejas D, Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky DB, Schlatzer D, Cooper M, Kiselar J, Stachnik A, Yao S, Hoon D, McQuaid D, Zaware N, Gong Y, Brautigan DL, Plymate SR, Sprenger CCT, Oh WK, Levine AC, Kirschenbaum A, Sfakianos JP, Sears R, DiFeo A, Ioannou Y, Ohlmeyer M, Narla G, Galsky MD.

Cancer Res. 2018 Apr 15;78(8):2065-2080. doi: 10.1158/0008-5472.CAN-17-0123. Epub 2018 Jan 22.

39.

The role of targeted therapy in the management of patients with AML.

Perl AE.

Blood Adv. 2017 Nov 14;1(24):2281-2294. doi: 10.1182/bloodadvances.2017009829. eCollection 2017 Nov 14. Review.

40.

The most novel of the novel agents for acute myeloid leukemia.

Perl AE.

Curr Opin Hematol. 2018 Mar;25(2):81-89. doi: 10.1097/MOH.0000000000000411. Review.

PMID:
29278535
41.

The role of targeted therapy in the management of patients with AML.

Perl AE.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):54-65. doi: 10.1182/asheducation-2017.1.54. Review.

43.

Sweet syndrome in patients with and without malignancy: A retrospective analysis of 83 patients from a tertiary academic referral center.

Nelson CA, Noe MH, McMahon CM, Gowda A, Wu B, Ashchyan HJ, Perl AE, James WD, Micheletti RG, Rosenbach M.

J Am Acad Dermatol. 2018 Feb;78(2):303-309.e4. doi: 10.1016/j.jaad.2017.09.013. Epub 2017 Oct 26.

PMID:
29107342
44.

Therapeutic targeting of PP2A.

O'Connor CM, Perl A, Leonard D, Sangodkar J, Narla G.

Int J Biochem Cell Biol. 2018 Mar;96:182-193. doi: 10.1016/j.biocel.2017.10.008. Epub 2017 Oct 26. Review.

45.

A "GLI-tch" in Alveolar Myofibroblast Differentiation.

Ahlfeld SK, Perl AK.

Am J Respir Cell Mol Biol. 2017 Sep;57(3):261-262. doi: 10.1165/rcmb.2017-0148ED. No abstract available.

46.

Review: Metabolic Control of Immune System Activation in Rheumatic Diseases.

Perl A.

Arthritis Rheumatol. 2017 Dec;69(12):2259-2270. doi: 10.1002/art.40223. Epub 2017 Nov 8. Review.

47.

Dataset on transcriptional profiles and the developmental characteristics of PDGFRα expressing lung fibroblasts.

Endale M, Ahlfeld S, Bao E, Chen X, Green J, Bess Z, Weirauch M, Xu Y, Perl AK.

Data Brief. 2017 Jun 7;13:415-431. doi: 10.1016/j.dib.2017.06.001. eCollection 2017 Aug.

48.

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.

Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis M.

Lancet Oncol. 2017 Aug;18(8):1061-1075. doi: 10.1016/S1470-2045(17)30416-3. Epub 2017 Jun 20. Erratum in: Lancet Oncol. 2017 Dec;18(12 ):e711. Lancet Oncol. 2018 Jul;19(7):e335. Lancet Oncol. 2019 Jun;20(6):e293.

49.

A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220.

Hou P, Wu C, Wang Y, Qi R, Bhavanasi D, Zuo Z, Dos Santos C, Chen S, Chen Y, Zheng H, Wang H, Perl A, Guo D, Huang J.

Cancer Res. 2017 Aug 15;77(16):4402-4413. doi: 10.1158/0008-5472.CAN-16-1627. Epub 2017 Jun 16.

50.

Phenylpyruvate Contributes to the Synthesis of Fragrant Benzenoid-Phenylpropanoids in Petunia × hybrida Flowers.

Oliva M, Bar E, Ovadia R, Perl A, Galili G, Lewinsohn E, Oren-Shamir M.

Front Plant Sci. 2017 May 12;8:769. doi: 10.3389/fpls.2017.00769. eCollection 2017.

Supplemental Content

Support Center